Previous 10 | Next 10 |
It may soon be time to short diabetes and NASH-focused stocks. Maybe not just yet, but turn on a Google Alert for "Revita", "duodenal mucosal resurfacing" and "Fractyl Laboratories" and track developments over the next few months. Here's why. The solution to type II diabetes and non-alcoholic ...
Introduction Albireo ( ALBO ) is one or the only publicly-listed biopharma that has an orphan pediatric cholestatic liver diseases clinical program. Albireo through its unique drug pipeline employs a distinct mechanistic approach to dealing with the distressing adverse event of pruritus (i...
CymaBay Therapeutics ( CBAY ) had a rough day last week when it reported results from its phase 2 study using its drug seladelpar to treat patients with nonalcoholic steatophepatitis (NASH). That's because it was shown that treatment with seladelpar failed to be statistically significa...
Intercept Pharmaceuticals ( ICPT +0.6% ) has rebounded from the session low of $78.21 on the heels of bullish comments from RBC that recent concerns with the potential FDA nod for obeticholic acid in NASH are unfounded. More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks new...
Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty l...
Thinly traded nano cap ContraVir Pharmaceuticals (NASDAQ: CTRV ) is up 139% premarket on increased volume in reaction to positive preclinical data on NASH candidate CRV431. More news on: ContraVir Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Healthcare stocks news,...
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its management will be presen...
Investment Thesis Pfizer (PFE) is a large-cap ($232B) global biopharmaceutical company widely known for the development of the blockbuster cardiovascular drug, Lipitor. Lipitor is perhaps the most recognized statin drug that is used clinically and over the counter to lower bad cholesterol,...
Genfit ( GNFT ) is gearing up for an explosive end to 2019. That's because it is expected to release interim results from its phase 3 NASH study by the end of 2019. This will be a major inflection point for the biotech, because it could determine whether or not it will be successful in the N...
Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...